Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Trop Pediatr ; 69(1)2022 12 05.
Article in English | MEDLINE | ID: covidwho-2299766

ABSTRACT

INTRODUCTION: Neonatal sepsis is a major cause of morbidity and mortality with a higher burden from the low- and middle-income countries. The coronavirus disease 2019 (Covid 19) pandemic has impacted healthcare in various ways including healthcare-associated infections (HAI). The objective of the present study was to determine changes in organism profile and incidence rates of HAI in neonates admitted to the index hospital during the pandemic and compared it with the data from the pre-pandemic period. MATERIALS AND METHODS: The study design was a retrospective, observational analysis of data from neonates with culture-positive sepsis, in a tertiary care children's hospital, between January 2018 and December 2021. Pre-Covid (January 2018 to December 2019) and Covid period data (January 2020 to December 2021) were analyzed for the significance of change. RESULTS: The prevalence of culture-positive sepsis, in pre-Covid and Covid periods, was 19.55% [95% confidence interval (95% CI) 17.13-21.52)] and 18.36% (CI 16.05-20.74), respectively. HAI rates/1000 patient days increased slightly during the Covid pandemic [7.2% (95% CI 6.98-10.08) to 9.8% (95% CI 9.78-13.67)] mainly due to an increase in fungal HAI (26% pre- vs. 41.5% Covid period). However, the proportion of Gram-negative (GN) infections fell significantly (70.5% vs. 48.6%) during the same period. In the pre-Covid period, Klebsiella followed by Burkholderia cepacia, Acinetobacter spp and Pseudomonas, were the major HAI isolates. During the Covid period, there was a decline in these isolates and Burkholderia spp was not detected. All fungal isolates were Candida species. The case fatality ratio (CFR) from HAI decreased significantly from 38% to 15.45%, mainly due to a decrease in GN HAI. CONCLUSION: During Covid pandemic, there was a significant decline in GN HAI and CFR from HAI, due to improved compliance with infection control measures in the neonatal intensive care unit (NICU). At the same time, there was a rise in the fungal HAI, possibly because of a higher proportion of premature, and sick neonates with longer hospital stay and more invasive procedures. Consolidations of gains in infection control and restriction of invasive procedures could help to minimize HAI in NICUs.


Blood stream infections in children less than 4 weeks old are known as neonatal sepsis. Several predisposing factors can make a neonate (less than 4 weeks) more prone to sepsis, such as prematurity, male gender, cultural practices, presence of underlying medical or surgical conditions, hospitalization, antibiotic use and invasive treatment. Neonatal sepsis in a hospitalized child can be either­pre-harbored infection (PHI), which means infection acquired prior to hospital admission or it could be healthcare-associated infection (HAI), where the infection is acquired during the hospital stay. Organisms causing neonatal sepsis in hospitalized neonates include bacteria and fungi. The coronavirus disease 2019 (Covid 19) pandemic impacted all aspects of life including healthcare. The investigators conducted the present study to look into the changes in the incidence rate as well as in the type of organisms causing healthcare-associated blood stream infections in neonates in the pre-Covid and during the Covid period.


Subject(s)
COVID-19 , Cross Infection , Neonatal Sepsis , Sepsis , Child , Humans , Infant, Newborn , Anti-Bacterial Agents/therapeutic use , COVID-19/epidemiology , Cross Infection/microbiology , Gram-Negative Bacteria , India/epidemiology , Intensive Care Units, Neonatal , Neonatal Sepsis/drug therapy , Retrospective Studies , Sepsis/epidemiology , Sepsis/drug therapy
3.
Pediatr Infect Dis J ; 41(6): 482-489, 2022 06 01.
Article in English | MEDLINE | ID: covidwho-1707086

ABSTRACT

BACKGROUND: We compared the hospital-based epidemiology of neonatal sepsis after the coronavirus disease 2019 lockdown (LD) versus historical epochs and the LD period versus phases of unlocking. METHODS: This retrospective cohort study was conducted in a level 3 neonatal unit. We compared neonates born in three 24-week periods-Group LD: 22 March 2020 to 5 September 2020-the reference group, Group pre-LD: 29 September 2019 to 14 March 2020 and Group temporally corresponding to LD in 2019 (corres-LD): 24 March 2019 to 7 September 2019. We also studied linear trends from LD phase 1.0 until Unlock 4.0. The key outcome was culture-positive sepsis. RESULTS: There were 1622, 2744 and 2700 subjects in groups LD, pre-LD and corres-LD, respectively. The incidence of any culture-positive sepsis in pre-LD was higher than LD [odds ratio (95% CI) = 1.61 (1.02-2.56)]. This was mainly due to a statistically significant reduction in Acinetobacter baumannii sepsis, with incidence rate differences of pre-LD versus LD [0.67 (95% CI: 0.37-0.97), P = 0.0001] and corres-LD versus LD [0.40 (95% CI: 0.16-0.64), P = 0.0024]. Groups pre-LD and corres-LD had higher proportion of multi-drug resistant (MDR)/extreme drug resistance/pan drug resistance sepsis than LD [77%, 77% and 44%, respectively (P values of both groups vs. LD = 0.01)]. From LD 1.0 to unlock 4.0, there were fewer episodes of MDR sepsis (Plinear trends = 0.047). On multivariable analysis, group pre-LD (vs. reference group LD), male sex, birth weight and Apgar score independently predicted culture-positive sepsis. CONCLUSIONS: LD favorably impacted the epidemiology of neonatal sepsis in a hospital setting, with less A. baumannii and MDR sepsis, which persisted during unlocking.


Subject(s)
COVID-19 , Neonatal Sepsis , Sepsis , Anti-Bacterial Agents/therapeutic use , COVID-19/epidemiology , Communicable Disease Control , Humans , Infant, Newborn , Male , Neonatal Sepsis/drug therapy , Neonatal Sepsis/epidemiology , Retrospective Studies , Sepsis/drug therapy , Sepsis/epidemiology
4.
Am J Perinatol ; 37(S 02): S5-S9, 2020 09.
Article in English | MEDLINE | ID: covidwho-752411

ABSTRACT

Despite continued advances and developments in neonatal medicine, neonatal sepsis is the third leading cause of neonatal mortality and a major public health problem, especially in developing countries. Sepsis accounts for mortality for almost 50% of global children under 5 years of age.Over the past 50 years, there have been many advances in the diagnosis, prevention, and treatment of neonatal infections. The diagnostic advances include better culture techniques that permit more rapid confirmation of the diagnosis, advent of polymerase chain reaction (PCR) to rapidly diagnose viral infections, use of biologic markers indicating evidence of infection, and a better understanding of immunoglobulin markers of infection. From a therapeutic stand point, there have been a variety of antibiotics, antifungals, and antiviral agents, better approaches to prevent sepsis, specific immunotherapy, for example, respiratory syncytial virus (RSV); bundled approach to prevention of deep-line infection and better antibiotic stewardship, leading to earlier discontinuation of antibiotic therapy.Hand hygiene remains the benchmark and gold standard for late-onset sepsis prevention. The challenge has been that each decade, newer resistant bacteria dominate as the cause of sepsis and newer viruses emerge, for example, human immunodeficiency virus, zika virus, and novel coronavirus disease 2019.Future treatment options might include stem cell therapy, other antimicrobial protein and peptides, and targeting of pattern recognition receptors in an effort to prevent and/or treat sepsis in this vulnerable population. Also, the microbiome of premature infants has a smaller proportion of beneficial bacteria and higher numbers of pathogenic bacteria compared with term infants, likely owing to higher frequencies of cesarean sections, antibiotic use, exposure to the hospital environment, and feeding nonhuman milk products. Modifying the microbiome with more mother's milk and shorter duration of antibiotics in noninfected babies should be a goal. KEY POINTS: · Neonatal sepsis remains a leading cause of mortality.. · Challenges include bacterial resistance and newer viruses.. · Future treatments may include newer antibiotics/antivirals and stem cell therapy..


Subject(s)
Anti-Bacterial Agents/therapeutic use , Intensive Care Units, Neonatal , Neonatal Sepsis/mortality , Neonatal Sepsis/prevention & control , Antiviral Agents/therapeutic use , Drug Resistance, Bacterial , Female , Humans , Infant , Infant Mortality , Infant, Newborn , Infant, Premature , Infant, Premature, Diseases/mortality , Infant, Premature, Diseases/prevention & control , Neonatal Sepsis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL